← All diseases Cancer

Chronic lymphocytic leukemia

Automatically tracked from PubMed and ClinicalTrials.gov, newest on top. Nothing ever disappears here: what you keep in your favorites remains findable. · RSS feed of this disease · only the strongest evidence

Search Period All yearsLast 12 monthsLast 5 years Topic All topicsGeneralNutrition and dietAlternative treatment methods Type of research Any type of researchStrongest evidence only (63)Meta-analysis (7)Treatment guideline (3)Phase 3 study (32)Systematic review (13)Randomized trial (8)Clinical trial (585)Review article (208)Early study (phase 1 or 2) (42)Case report (197)Laboratory or animal study (14)Commentary or editorial (62)Retracted publication (2) Studies currently seeking participants only (48)

Filter

Publications and studies (1772)

• Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation. (2019/02/15) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. The Expanding Field of Secondary Antibody Deficiency: Causes, Diagnosis, and Management. (2019/02/08) ♡
• Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis. (2019/02/01) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. First-Line Ibrutinib Confirmed for CLL. (2019/02/01) ♡
• Phase 3 studyiResearch in a large group of patients, the final step before a treatment can be approved. What comes out here carries significant weight. Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study. (2019/02/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. The importance of B cell receptor isotypes and stereotypes in chronic lymphocytic leukemia. (2019/02/01) ♡
• Pathologic Findings in Bronchopulmonary Leukemic Infiltrates in Patients With Chronic Lymphocytic Leukemia. (2019/02/01) ♡
• Systematic tracking of altered modules identifies the key biomarkers involved in chronic lymphocytic leukemia. (2019/02/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Disseminated mucormycosis due to Lichtheimia corymbifera during ibrutinib treatment for relapsed chronic lymphocytic leukaemia: a case report. (2019/02/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Metabolic rewiring beyond Warburg in chronic lymphocytic leukemia: How much do we actually know? (2019/02/01) ♡
• Experiences in the treatment of refractory chylothorax associated with lymphoproliferative disorders. (2019/01/09) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Current trends in the management of Richter's syndrome. (2019/01/08) ♡
• Global distribution of DNA hydroxymethylation and DNA methylation in chronic lymphocytic leukemia. (2019/01/07) ♡
• Ibrutinib: searching for a partner drug. (2019/01/01) ♡
• Phase 3 studyiResearch in a large group of patients, the final step before a treatment can be approved. What comes out here carries significant weight. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. (2019/01/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. The applications of anti-CD20 antibodies to treat various B cells disorders. (2019/01/01) ♡
• Early-stage study (phase 1 or 2)iEarly research in a small group, primarily aimed at safety and dosage. Whether it actually works still needs to be determined afterward. Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study. (2019/01/01) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. Concurrent treatment with two B-cell receptor pathway inhibitors. (2019/01/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Successful treatment with ribavirine for chronic hepatitis E in chronic lymphocytic leukemia treated with Ibrutinib. (2019/01/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Noncoding RNA genes in cancer pathogenesis. (2019/01/01) ♡
• Effects of complement and serum IgG on rituximab-dependent natural killer cell-mediated cytotoxicity against Raji cells. (2019/01/01) ♡
• Increased serum levels of Galectin-9 in patients with chronic lymphocytic leukemia. (2019/01/01) ♡
• Study of microRNA Profile as a Molecular Biomarker in Egyptian Chronic Lymphocytic Leukemia. (2019/01/01) ♡
• Measurement of Leukemic B-Cell Growth Kinetics in Patients with Chronic Lymphocytic Leukemia. (2019/01/01) ♡
• Expression and Effects of Ligand-activated Estrogen Receptors in Chronic Lymphocytic Leukemia. (2019/01/01) ♡
• Early-stage study (phase 1 or 2)iEarly research in a small group, primarily aimed at safety and dosage. Whether it actually works still needs to be determined afterward. Phase I study of ibrutinib in Japanese patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma. (2019/01/01) ♡
• Phase 3 studyiResearch in a large group of patients, the final step before a treatment can be approved. What comes out here carries significant weight. Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. (2018/12/27) ♡
• Limited value of routine follow-up visits in chronic lymphocytic leukemia managed initially by watch and wait: A North Denmark population-based study. (2018/12/27) ♡
• Obinutuzumab pretreatment abrogates tumor lysis risk while maintaining undetectable MRD for venetoclax + obinutuzumab in CLL. (2018/12/26) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. The Direct Antiglobulin Test for Evaluating Anemia. (2018/12/25) ♡
• CD200 Expression in Diagnostic and Prognostic Assessment of Mature B Cell Lymphophoproliferative Neoplasms. (2018/12/25) ♡
• Droplet digital PCR for the quantification of Alu methylation status in hematological malignancies. (2018/12/22) ♡
• Comprehensive Genomic Profiling Reveals Diverse but Actionable Molecular Portfolios across Hematologic Malignancies: Implications for Next Generation Clinical Trials. (2018/12/21) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Genetic correlation between multiple myeloma and chronic lymphocytic leukaemia provides evidence for shared aetiology. (2018/12/21) ♡
• Investigating epigenetic effects of activation-induced deaminase in chronic lymphocytic leukemia. (2018/12/20) ♡
• Chronic lymphocytic leukemia cells from ibrutinib treated patients are sensitive to Axl receptor tyrosine kinase inhibitor therapy. (2018/12/14) ♡
• The regulatory capacity of B cells directs the aggressiveness of CLL. (2018/12/12) ♡
• Ig-Like Transcript 2 (ILT2) Blockade and Lenalidomide Restore NK Cell Function in Chronic Lymphocytic Leukemia. (2018/12/11) ♡
• Enhancer Architecture and Essential Core Regulatory Circuitry of Chronic Lymphocytic Leukemia. (2018/12/10) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. From Basic Knowledge to Effective Therapies. (2018/12/10) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. BH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines. (2018/12/10) ♡
• [Diagnostic and therapeutic values of interphase fluorescence in situ hybridization in B-cell lymphomas: a clinicopathologic analysis of 604 cases]. (2018/12/08) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. DUO delivers for duvelisib. (2018/12/06) ♡
• Cryopreservation of primary B cells minimally influences their signaling responses. (2018/12/05) ♡
• A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia. (2018/12/04) ♡
• [Characteristics of CD180 Expression and Its Diagnostic Value in B Cell Chronic Lymphoproliferative Disorders]. (2018/12/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Management of unfit elderly patients with chronic lymphocytic leukemia. (2018/12/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Targeted Therapies in CLL: Monotherapy Versus Combination Approaches. (2018/12/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Assessing copy number aberrations and copy-neutral loss-of-heterozygosity across the genome as best practice: An evidence-based review from the Cancer Genomics Consortium (CGC) working group for chronic lymphocytic leukemia. (2018/12/01) ♡
• THE SPECTRUM OF TP53, SF3B1, AND NOTCH1 MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS EXPOSED TO IONIZING RADIATION DUE TO THE CHORNOBYL NPP ACCIDENT. (2018/12/01) ♡

↑ Back to top

codex.care does not provide medical advice. Always discuss symptoms, medication, and treatment choices with your own healthcare provider.